CASE REPORT
Year : 2016 | Volume
: 11 | Issue : 4 | Page : 289--293
Dasatinib-induced pleural effusion: Chylothorax, an option to consider
Lucia Ferreiro1, Esther San-Jose2, Juan Suarez-Antelo3, Luis Valdes1
1 Department of Pulmonology; Interdisciplinary Research Group in Pulmonology, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, A Coruña, Spain
2 Interdisciplinary Research Group in Pulmonology, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela; Department of Clinical Analysis, University Clinical Hospital of Santiago de Compostela, A Coruña, Spain
3 Department of Pulmonology, University Clinical Hospital of Santiago de Compostela, A Coruña, Spain
Correspondence Address:
Lucia Ferreiro
Department of Pulmonology, University Clinical Hospital of Santiago de Compostela, Travesia A Choupana s/n, 15702 Santiago de Compostela, A Coruna
Spain
Dasatinib is a drug for treatment of oncogene fusion protein BCR-ABL-positive chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant/intolerant to imatinib. Pleural effusion (PE) is a common adverse effect, and in this context, we present four cases seen due to this cause. One of them is a chylothorax. The PE grade is variable, and the physiopathology is not well established, although a block in T-lymphocyte function or inhibition of platelet-derived growth factor receptor-β is suggested being involved. The PE is generally a lymphocyte-predominant exudate, but can also present as chylothorax. Several factors have been associated with its appearance, particularly the administration in two daily doses. Low grade (1–2) PEs usually respond well to interrupt the treatment while those of higher grade may also require therapeutic thoracentesis and corticosteroids. There are currently no firm guidelines that establish when to resort to one form of treatment or another.
How to cite this article:
Ferreiro L, San-Jose E, Suarez-Antelo J, Valdes L. Dasatinib-induced pleural effusion: Chylothorax, an option to consider.Ann Thorac Med 2016;11:289-293
|
How to cite this URL:
Ferreiro L, San-Jose E, Suarez-Antelo J, Valdes L. Dasatinib-induced pleural effusion: Chylothorax, an option to consider. Ann Thorac Med [serial online] 2016 [cited 2023 Mar 24 ];11:289-293
Available from: https://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2016;volume=11;issue=4;spage=289;epage=293;aulast=Ferreiro;type=0 |
|
|
|
